Latest Interim Results News

Amplia Therapeutics reported a $4.18 million half-year loss but bolstered its cash reserves with a $27.6 million capital raise to advance clinical trials of its lead drug narmafotinib, showing encouraging interim data in pancreatic cancer.

Straker Limited has significantly narrowed its interim loss despite a 15% revenue decline, driven by cost efficiencies and the absence of prior non-cash charges. The company also renewed a strategic $28 million partnership with IBM, reinforcing its AI language technology ambitions.

Australian Foundation Investment Company plans special fully franked dividends alongside its 2026 interim and final payouts, leveraging a strong franking credit balance.

Oceania Healthcare Limited reported a robust 1HY26 performance, marked by increased sales volumes, improved care profitability, and disciplined capital management. The company’s strategic focus on sales, operational excellence, and debt reduction sets a solid foundation for sustainable growth.

Oceania Healthcare reports a robust interim result for the six months to September 2025, with significant earnings growth, improved sales, and a reduction in debt gearing. The company’s strategic focus on cost control, capital management, and sustainable care delivery underpins its positive outlook despite housing market headwinds.

Oceania Healthcare reported a slight dip in revenue but impressive gains in profitability for the first half of 2025, highlighting operational resilience amid a challenging environment.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

Serko Limited reports a robust 45% increase in total income for the first half of FY26, driven by its GetThere acquisition and strong momentum in Booking.com for Business, alongside a significant uplift in EBITDAFI.

Besra Gold Inc. reported a $3.47 million loss for Q1 2026, weighed down by finance costs tied to a major gold purchase agreement. Despite asset impairments and net liabilities, management remains cautiously optimistic about ongoing funding and project development.

Alkane Resources reports its Q1 FY2026 interim results, highlighting the integration of Mandalay Resources and key operational developments across its global mining portfolio.

Chimeric Therapeutics reports promising interim results from its CHM CDH17 Phase 1/2 trial, with 75% disease control at 28 days and durable responses in gastrointestinal cancers.

Xero Limited reported a robust first half of FY26 with 20% revenue growth and strong cash generation, driven by sustained momentum across its core markets and the strategic Melio acquisition expanding its US footprint.